Serologicals Corporation, a global provider of biological products and enabling technologies, announced that it has expanded its agreement with Novo Nordisk (Bagsvaerd, Denmark) for worldwide distribution of Human Recombinant Insulin for use in Cell Culture media markets thru 2006. Terms of the agreement were not disclosed.
Insulin is a major part of the Serologicals portfolio of leading cell culture products, which include the patented EX-CYTE, the Company's proprietary Bovine Serum Albumin (BSA) product line, Transferrin and other related cell culture supplements.
"We're pleased to continue our excellent relationship with Novo Nordisk," said David A. Dodd, president and chief executive officer for Serologicals Corporation. "These products make up an important part of our cell culture portfolio, providing our customers the products they need as they develop and commercialize life enhancing technologies that benefit us all." "This Agreement with Serologicals Corporation continues Novo Nordisk's long term business relationship together and is an important segment and diversification in Novo Nordisk's existing business," added Witte Rijnberg, Novo Nordisk's International Operations Senior VP.